aTyr Pharma, Inc.
ATYR
$5.35
$0.408.08%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -100.00% | -33.43% | -97.81% | -94.34% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -100.00% | -33.43% | -97.81% | -94.34% |
| Cost of Revenue | 7.58% | 14.14% | 28.56% | 23.51% | 14.58% |
| Gross Profit | -8.85% | -15.61% | -29.08% | -62.16% | -48.24% |
| SG&A Expenses | 24.52% | 8.80% | 6.15% | 1.42% | -10.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.99% | 12.96% | 23.30% | 18.45% | 8.49% |
| Operating Income | -12.03% | -14.09% | -23.66% | -45.07% | -30.84% |
| Income Before Tax | -15.11% | -17.59% | -27.04% | -47.86% | -28.48% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.11% | -17.59% | -27.04% | -47.86% | -28.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 600.00% | 33.33% | -112.50% | -111.11% | -112.50% |
| Net Income | -15.10% | -17.58% | -27.06% | -47.89% | -28.51% |
| EBIT | -12.03% | -14.09% | -23.66% | -45.07% | -30.84% |
| EBITDA | -12.20% | -14.25% | -23.71% | -44.97% | -30.26% |
| EPS Basic | 11.89% | 10.72% | 8.94% | 2.73% | 26.38% |
| Normalized Basic EPS | 11.90% | 10.72% | 8.94% | 2.72% | 26.38% |
| EPS Diluted | 11.89% | 10.72% | 8.94% | 2.73% | 26.38% |
| Normalized Diluted EPS | 11.90% | 10.72% | 8.94% | 2.72% | 26.38% |
| Average Basic Shares Outstanding | 31.16% | 33.11% | 38.61% | 48.57% | 65.04% |
| Average Diluted Shares Outstanding | 31.16% | 33.11% | 38.61% | 48.57% | 65.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |